Previous Close | 20.13 |
Open | 20.10 |
Bid | 20.43 x 800 |
Ask | 21.98 x 1400 |
Day's Range | 19.77 - 20.60 |
52 Week Range | 15.45 - 33.31 |
Volume | |
Avg. Volume | 1,188,315 |
Market Cap | 2.796B |
Beta (5Y Monthly) | 1.33 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.06 |
Earnings Date | May 06, 2024 - May 10, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 43.56 |
Subscribe to Yahoo Finance Plus to view Fair Value for DNLI
Denali (DNLI) reports lower than expected fourth-quarter financial results. The stock, however, rises 38% on news of funding raised by the company, which is expected to strengthen its cash position.
Highlights Strategic Progress and Clinical Developments
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today reported financial results for the fourth quarter and year ended December 31, 2023, and provided business highlights. "2023 was a year of significant progress across our broad thera